Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of Brigimadlin (BI 907828) Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma

NCT05218499 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05218499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05218499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of Brigimadlin (BI 907828) Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2022
Completion date
January 26, 2026
Enrollment
400 (actual)
Sites
109

Conditions

As the registry lists them; a condition with its own page is linked.

liposarcoma, dedifferentiated